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DNA damage responsea b s t r a c t
Aim: To correlate residual double strand breaks (DSB) 24 h after 4 Gy test doses to skin in vivo and to lym-
phocytes in vitro with adverse effects of earlier breast radiotherapy (RT).
Patients and methods: Patients given whole breast RT P5 years earlier were identified on the basis of
moderate/marked or minimal/no adverse effects despite the absence (‘RT-Sensitive’, RT-S) or presence
(‘RT-Resistant’, RT-R) of variables predisposing to late adverse effects. Residual DSB were quantified in
skin 24 h after a 4 Gy test dose in 20 RT-S and 15 RT-R patients. Residual DSB were quantified in lympho-
cytes irradiated with 4 Gy in vitro in 30/35 patients.
Results: Mean foci per dermal fibroblast were 3.29 (RT-S) vs 2.80 (RT-R) (p = 0.137); 3.28 (RT-S) vs 2.60
(RT-R) in endothelium (p = 0.158); 2.50 (RT-S) vs 2.41 (RT-R) in suprabasal keratinocytes (p = 0.633); 2.70
(RT-S) vs 2.35 (RT-R) in basal epidermis (p = 0.419); 12.1 (RT-S) vs 10.3 (RT-R) in lymphocytes
(p = 0.0052).
Conclusions: Residual DSB in skin following a 4 Gy dose were not significantly associated with risk of late
adverse effects of breast radiotherapy, although exploratory analyses suggested an association in severely
affected individuals. By contrast, a significant association was detected based on the in vitro response of
lymphocytes.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 244–249
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nd/4.0/).Processes determining cellular radiosensitivity include the
recognition and repair of DNA double strand breaks (DSB), inher-
ited defects which account for clinical radiosensitivity in rare indi-
viduals [1]. Contrary to the early small case–control clinical studies
that suggested a correlation between in vitro cellular radiosensitiv-
ity and late normal tissue damage after radiotherapy, later studies
seeking to test the DNA damage response as a predictor of normal
tissue radiosensitivity have been inconclusive [2–6]. A relevant
criticism of all these studies has been that in vitro cellular
responses may correlate poorly with in vivo cellular responses
due to the modifying influence of tissue environment [7,8]. Thereported lack of correlation between the severity of fibrosis and
telangiectasia risks after post-mastectomy radiotherapy also
suggests that predictive cellular assays need to be endpoint-
specific [9]. In the case of subcutaneous fibrosis and cutaneous
telangiectasia, for example, this implies the need to measure cellu-
lar responses in dermal fibroblasts and dermal endothelial cells,
respectively. Given that much of the DNA damage response is com-
mon to all cell types, lymphocytes justify investigation by virtue of
easy availability and the results of earlier studies [10–12]. Here, we
report on residual DSB in different skin cell types 24 h after an
in vivo test dose of 4 Gy in a group of 35 individuals selected on
the basis of their radiation-induced adverse effects following
breast radiotherapy. We also report on residual DSB in in vitro irra-
diated G0 blood lymphocytes from 30/35 individuals, including 16
previously published [13,14].
Table 2
Characteristics and treatment parameters of ‘radiosensitive’ (RT-S) and ‘radioresis-
tant’ (RT-R) patients.
RT-S RT-R
Patients (n = 35) 20 15
Median age, years (range) 70 (52–83) 68 (54–78)
Median follow-up, years (range) 11 (3–24) 13 (11–24)




Number patients prescribed boost dose 15 15








Large 4 (1 mastectomy2) 1
Axillary treatment 15 11
Tamoxifen 14 12
Chemotherapy 8 15
1 Equivalent total dose assuming a/b = 3 Gy.
2 Patient had mastectomy & reconstruction before RT; this was the only patient
with <5 yr follow up.
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Selection of clinically radiosensitive (RT-S) and radioresistant (RT-R)
individuals
All participants were former breast cancer patients enrolled in
two breast radiotherapy trials; the START pilot trial (N = 1410)
and the Royal Marsden breast dosimetry trial (N = 306). Both trials
delivered treatment according to a predefined protocol and
included prospective annual clinical assessments of late adverse
effects [15,16]. In addition to clinical assessments, late adverse
effects were evaluated using pre- and post-treatment photographs
of both breasts collected under predefined conditions at 0, 1, 2, and
5 years [15,17]. Multivariate analysis identified and ranked factors
associated with photographic change in breast appearance, includ-
ing prescribed whole breast radiotherapy dose, radiation dosime-
try, radiotherapy boost to tumour bed, breast size, proportion of
breast removed at surgery, and axillary treatment, see Table 1.
These parameters were used to identify patients with marked
adverse effects despite favourable parameters (‘radiosensitive’
(RT-S)) and unmatched patients (‘radioresistant’, (RT-R)) with no
changes despite unfavourable parameters. This approach
attempted to generate maximum separation in terms of intrinsic
factors predisposing to the presence or absence of late adverse
effects, chiefly breast shrinkage. After identifying potentially eligi-
ble individuals according to the above criteria, a final selection was
made by two clinicians (JY and NS) to exclude individuals in whom
factors omitted by the algorithmwere considered to strongly influ-
ence clinical response. The commonest reason was breast shrink-
age and/or distortion in a patient with an inferior quadrant
tumour, where irregular breast contour after wide surgical resec-
tion followed by 2D radiation dosimetry was considered sufficient
explanation for late changes unaccounted for by multivariate anal-
ysis. Ethical approval was obtained from the Royal Marsden
Research Ethics Committee, and written consent was obtained
from patients prior to participation.Skin irradiation, 53BP1 immunohistochemistry, and foci analyses of
skin sections
A test dose of 4 Gy was delivered to an area of buttock skin
measuring 2  4 cm using 6 MeV electrons via a purpose-built
end-frame, ensuring dose homogeneity to the epidermis and
dermis as described previously [18]. Paired 4 mm biopsies were
collected from the centre of the irradiated area 24 h post-
irradiation and from unirradiated skin on the opposite buttock.Table 1
Risk factors for late adverse effects following breast radiotherapy established by
multivariate analyses of outcomes of two breast radiotherapy trials [15,16]. Odds
ratios are presented relative to favourable factors: lower radiotherapy dose, 3D
dosimetry, no boost dose, small breast size, minimal surgical cavity and no axillary
radiotherapy.
Clinical parameters Odds ratio for late RT-induced effects
(95% CI)
RT dose (39, 42.9 or 50 Gy)1 1.09 (1.01–1.17), p = 0.02
Radiation dosimetry (3D dosimetry
vs standard 2D wedge)
1.71 (1.15–2.54), p = 0.008
Boost dose to tumour bed (none,
11.1 or 15.5 Gy)2
1.03 (1.02–1.05), p < 0.001
Surgical deficit (small, medium,
large)
Medium = 2.00 (1.23–3.25),
large = 1.38 (0.57–3.37), p = 0.009
Axillary treatment (none, surgery,
RT)
Surgery = 1.38 (0.72–2.63), RT = 2.49
(1.20–5.18), p = 0.05
1 Allowing for differences in fraction size, assuming a/b = 3 Gy.
2 Prescribed to 100% in 5 or 7 fractions (2.0 Gy to 90%), mostly commonly
electrons.53BP1 foci were scored in dermal fibroblasts, dermal endothelial
cells, suprabasal keratinocytes and basal keratinocytes, with
50–100 cells scored for each cell type per biopsy of each patient.
Details of tissue processing, 53BP1 immunostaining and foci
analyses have been described previously [18]. Residual DSB were
corrected for DSB in unirradiated control skin biopsied at the same
time.Dermal fibroblast cultures and in vitro irradiation
Patients were invited to donate a second set of paired skin biop-
sies from irradiated and unirradiated skin 12 weeks after the test
dose. Fibroblast cultures were established from unirradiated skin
for studies of in vitro sensitivity, as described [19].Peripheral blood separation, G0 blood lymphocyte irradiation and
residual DSB foci
Thirty patients from the same cohort consented to peripheral
blood sampling. As described in an earlier publication, G0 blood
lymphocytes were isolated from whole blood and irradiated to
4 Gy using 250 kV X-rays delivered at 0.69 Gy/min (Pantak, Surrey,
UK) [13,14]. DSB in irradiated blood lymphocytes were quantified
using cH2AX and 53BP1 immunostaining and co-localising cH2AX
and 53BP1 foci were scored 24 h after irradiation [13,14].Statistical methods
The study was designed to recruit 15 RT-S and 15 RT-R patients
with the aim of detecting a standardised difference of 1.2 with 85%
power (5% two-sided significance level). Comparative analyses of
clinical parameters and foci levels between RT-S and RT-R patients
were performed using the Mann–Whitney U test. Spearman’s rank
correlation test was used to test for correlation of residual foci
levels in the different cell types and clinical severity of late effects
among RT-S patients. However, as these tests of association were
secondary analyses undertaken on an exploratory basis, conserva-
tive p-values (p < 0.01) were employed in their interpretation.
Statistical calculations were performed using SPSS version 21.0.
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Patients
Of 35 breast radiotherapy patients who consented for the study,
20 and 15 were recruited as RT-S and RT-R patients, respectively.
More potential RT-S candidates were available and offered consent,
resulting in 5 additional patients in this group. Patient characteris-
tics and treatment-related parameters are summarised in Table 2.Correlation between residual DSB foci in different skin cell types after a
4 Gy test dose in vivo and to blood lymphocytes and dermal fibroblasts
irradiated in vitro
Residual DSB counted in dermal fibroblasts, endothelial cells,
basal keratinocytes and suprabasal keratinocytes in skin sections
collected 24 h after the 4 Gy in vivo test dose, corrected for DSB
in unirradiated control skin biopsied at the same time, are shown
in Supplementary Table S1, which also includes corrected foci
counts for in vitro irradiated dermal fibroblasts and blood G0Fig. 1. Individual DSB foci levels scored in irradiated skin of RT-S and RT-R patients 24
with dashed lines representing one standard deviation. The squared symbols in fifth palymphocytes. Patients (first column) are numbered according to
increasing levels of residual DSB in dermal fibroblasts irradiated
in vivo (second column). The colour washes identify DSB grouped
in quartiles (9 + 9 + 8 + 9 = 35), red identifying the quartile with
the highest DSB for each cell type. Correlation between different
cell types is shown in Supplementary Table S2, suggesting a signif-
icant correlation restricted to in vivo irradiated dermal fibroblasts,
endothelial cells and suprabasal keratinocytes.Residual DSB foci levels in irradiated skin and G0 lymphocytes in RT-S
and RT-R patients
Patient-averaged residual DSB 24 h after 4 Gy to skin and mea-
sured in epidermal and dermal skin cells did not differ significantly
between RT-S and RT-R patients, see Fig. 1. Mean foci per cell were
3.29 (RT-S) and 2.80 (RT-R) for dermal fibroblasts (p = 0.137), 3.28
(RT-S) and 2.60 (RT-R) for endothelial cells (p = 0.158), 2.50 (RT-S)
and 2.41 (RT-R) for suprabasal keratinocytes (p = 0.633), and 2.70
(RT-S) and 2.35 (RT-R) for basal keratinocytes (p = 0.419). Focih after 4 Gy in vivo. Horizontal lines represent patient-averaged residual foci levels
nel represent previously published data [13,14].
RT-S1 RT-S2
Sub-classification of RT-S patients
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significant difference between RT-S and RT-R patients (data not
shown).
We previously reported that DSB foci levels of G0 blood lympho-
cytes 24 h after 4 Gy X-rays ex vivowere higher in 8 RT-S compared
to 8 RT-R patients from the current cohort (p = 0.01), selected on
the basis that these 16/35 individuals appeared to represent the
two extremes of the response distribution [13,14]. We therefore
proceeded to test if foci levels in lymphocytes correlated with
severity of late radiation-induced skin changes in all 30 patients
offering blood samples. The association between residual DSB in
lymphocytes and adverse effects was significant, based on mean
foci levels of 12.1 (RT-S) and 10.3 (RT-R) (p = 0.0052),Fig. 2. Post-surgical photographs of two equal-sized (n = 10) exploratory RT-S
subgroups with moderate (left) and marked (right) degree of late effects in the
irradiated breast (grey arrow) at 5 years post-radiotherapy. Consent was obtained
from patients for the use of these photographs.Exploratory analyses of irradiated skin and G0 lymphocytes in RT-S1,
RT-S2 and RT-R patients
Although patient-averaged residual foci levels in in vivo irradi-
ated skin cells were not significantly different between ‘sensitive’
and ‘resistant’ groups, the variance was much larger among RT-S
than RT-R individuals, as seen in Fig. 1. This stimulated an explora-
tory analysis of residual foci levels according to the severity of late
radiation-induced skin changes in the 20 RT-S patients. Two equal-
sized subgroups, RT-S1 (less severe) and RT-S2 (more severe), were
selected by JY and NS blind to the residual DSB data. Illustrative
examples of patients classified under the respective groups are
shown in Fig. 2. The levels of association between residual foci
levels in the different skin cells and clinical severity in RT-S1 and
RT-S2 patients are shown in Fig. 3. Residual foci levels in dermal
fibroblasts were correlated with change in breast appearance in
RT-R and RT-S1 and RT-S2 patients (Spearman’s R2 = 0.248,
p = 0.002). There was a trend for association between residual foci
levels in endothelial cells and clinical severity for the same groups,
but this was not statistically significant (Spearman’s R2 = 0.158,
p = 0.018). No association was observed between residual foci
levels in keratinocytes and adverse effects (suprabasal keratinocytes,
Spearman’s R2 = 0.028, p = 0.334; basal keratinocytes, Spearman’s
R2 = 0.019, p = 0.433).
As for dermal fibroblasts, a positive patient-specific association
was observed between residual foci levels 24 h after 4 Gy
X-irradiation in blood lymphocytes and severity of adverse effects
in RT-R, RT-S1 and RT-S2 patients, see Fig. 3 (Spearman’s
R2 = 0.365, p < 0.001).Discussion
Mean levels of residual DSB foci in dermal fibroblasts measured
24 h after a 4 Gy in vivo test dose to buttock skin did not differ sig-
nificantly between RT-S and RT-R groups identified on the basis of
normal tissue effects, mainly breast shrinkage, >5 years after breast
radiotherapy. There were interesting trends, though: mean resid-
ual foci levels were 3.29 (RT-S) and 2.80 (RT-R) (p = 0.07) in dermal
fibroblasts, 3.28 (RT-S) and 2.60 (RT-R) (p = 0.08) in endothelial
cells. Only the association between residual DSB in lymphocytes
and adverse effects was significant, based on mean foci levels of
12.1 (RT-S) and 10.3 (RT-R) (p = 0.0052), extending the results of
an earlier series including 16 of the current cohort [13,14]. Notably,
the relative difference between RT-S and RT-R was identical (17–18%)
in fibroblasts and lymphocytes, and larger (26%) in endothelial
cells, supporting the notion that the differences may be real.
The main strength of the investigation lies in controlling for
potential effects of tissue microenvironment on cell responses,
measured using residual DSB as a surrogate endpoint that was
relevant to cell fate and late onset deterministic effects of treatment.
As such, it is the only clinical study known to us that has attemptedthis approach. A second strength is recruitment of patients under
prospective follow up according to standardised criteria that
allowed change in photographic breast appearance to be used as
an endpoint of proven sensitivity to small randomised differences
in dose [15,20]. In principle, the attempt to identify subgroups of
individuals whose change in breast appearance was unexpectedly
marked (RT-S) or unexpectedly mild/absent (RT-R) was a further
strength in that it avoided the need to identify matched controls
and selected individuals from opposite ends of the population sen-
sitivity distribution. In practice, however, patient selection proved
very difficult, as noted from the patient characteristics in Table 2,
for reasons including the relative crudeness of the algorithm, as
well as more practical issues related to consent. At a time when
RT-S patients were particularly difficult to recruit, one exceptional
patient was entered with a very marked radiation phenotype only
3 years after post-mastectomy latissimus dorsi flap reconstruction
and radiotherapy; but all other participants were trial patients as
planned. The marked differences in phenotype between RT-S
patients, as well as marked inter-patient variation in residual
DSB in this population, prompted an exploratory subgroup analysis
that suggests an association between residual DSB in dermal
fibroblasts irradiated in vivo and late adverse effects (Spearman’s
R = 0.498, p = 0.002) in addition to the association found for
lymphocytes. We consider that the RT-S1 subgroup represents
the 1–5% most responsive, i.e. dose-limiting, patients, while the
RT-S2 subgroup includes 6/10 patients whom we consider repre-
sent <1% of the population of radiotherapy patients. We could
not attempt any ranking of the RT-R group. It is clear from our
results that the reported associations are dependent on the most
severely affected individuals, albeit consistent with lymphocyte
responses as predictors of clinical risk reported by other colleagues
[10–12,21]. However, the findings of our study raise no expectation
that we can identify dose-limiting subgroups, a conclusion consis-
tent with Bentzen’s predictions almost 20 years ago [22].
A final comment might be made concerning the associations
between residual DSB in different skin cell types after in vivo or
in vitro irradiation, which are interesting in themselves, indepen-
dently of the lack of significant association with clinical outcome.
The colour wash in Supplementary Table S1 illustrates this most
clearly, suggesting that cell types with the lowest proliferative
indices, including dermal fibroblasts, dermal endothelial cells,
suprabasal keratinocytes and G0 blood lymphocytes stand in con-
trast to basal keratinocytes irradiated in vivo and in vitro cultured
dermal fibroblasts cultured from the same patients.
Fig. 3. Individual residual foci levels in the different skin cells for all RT-R and RT-S patients, with the latter divided into 2 equally-sized subgroups (RT-S1 & RT-S2) based on
severity of late effects in exploratory analyses. Horizontal lines represent patient-averaged foci levels for all patients classified under the same grade of clinical severity. R2
values were generated using Spearman’s rank correlation test. Squared symbols in fifth panel identify the patients for whom lymphocyte sensitivities have been previously
published [13,14]. Six individuals with exceptionally severe effects are marked with arrows.
248 DNA damage response & late adverse RT effectsConclusions
This study suggests that residual DSB in skin irradiated in vivo
are weakly associated with late normal tissue response to breast
radiotherapy, but that residual DSB of blood G0 lymphocytes irra-
diated in vitro have a closer relationship with clinical outcome.Role of funding source
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